International Journal of Medicine and Medical Research (IJMMR)

[1] Zaychenko GV, Simonov PV. Medical cannabis and cannabinoids in clinical practice: Pharmacological effects and risks. Health Technol Assessm. 2019;2(2):13 –17. Available from: https://librarynmu.com/images/PDFfile/Zaichenko.pdf

[2] Hinz B, Ramer R. Anti-tumour actions of cannabinoids. Br J Pharmacol. 2019;176(10):138–94. DOI: 10.1111/bph.14426

[3] Sulaieva O, Mashukov A, Kirkilevsky S. The tumour immune contexture and theranostic markers expression in patients with gastric carcinoma. Ann Oncol. 2020;31(Suppl 4):1115. DOI: 10.1016/j.annonc.2020.08.1300

[4]  Aliekperova N, Kosyachenko К, Kaniura O. Perspectives on formation of medical cannabis market in Ukraine based on holistic approach. J Cannabis Res. 2020;2:33. DOI: 10.1186/s42238-020-00044-y

[5] Aliekperova N, Kostiuk I, Hala L, Biliaeva A. Pharmacists’ opinions on the legalization of medical cannabis in Ukraine. Research J. Pharm. and Tech. 2023;16(4):1851–56. DOI: 10.52711/0974-360X.2023.00303

[6] Singh C, Rao K, Yadav N, Vashist Y, Chugh P, Bansal N, et al. Current cannabidiol safety: A review. Curr Drug Saf. 2023;18(4):465–73. DOI: 10.2174/1574886317666220902100511

[7] Liu L, Liu J, Zhao M, Cai M, Lei F, Zeng X, Zhu B. A bibliometrics and visualization analysis of cannabidiol research from 2004 to 2021. Front Pharmacol. 2022;13:969883. DOI: 10.3389/fphar.2022.969883

[8] Amin MR, Ali DW. Pharmacology of medical cannabis. Adv Exp Med Biol. 2019;1162:151–65. DOI: 10.1007/978-3-030-21737-2_8

[9] Adams R, Hunt M, Clark JH. Structure of cannabidiol, a product isolated from the marihuana extract of Minnesota wild hemp. I. J Am Chem Soc. 1940;62(1):196–200. DOI: 10.1021/ja01858a058

[10] Silvestro S, Mammana S, Cavalli E, Bramanti P, Mazzon E. Use of cannabidiol in the treatment of epilepsy: Efficacy and security in clinical trials. Molecules. 2019;24(8):1459. DOI: 10.3390/molecules24081459

[11] Parker LA, Rock EM, Mechoulam R. CBD: What Does the Science Say? [Internet]. Cambridge: The MIT Press; 2022 [cited 2023 Aug 17]. 320 p. DOI: 10.7551/mitpress/13686.001.0001

[12] Premoli M, Aria F, Bonini SA, Maccarinelli G, Gianoncelli A, Della Pina S, et al. Cannabidiol: Recent advances and new insights for neuropsychiatric disorders treatment. Life Sci. 2019;224:120–27. DOI: 10.1016/j.lfs.2019.03.053

[13] Raïch Iu, Rivas-Santisteban R, Lillo A, Lillo J, Reyes-Resina I, Nadal X, et al. Similarities and differences upon binding of naturally occurring Δ9-tetrahydrocannabinol-derivatives to cannabinoid CB1 and CB2 receptors. Pharmacol Res. 2021;174:105970. DOI: 10.1016/j.phrs.2021.105970

[14] Bosquez-Berger T, Gudorf JA, Kuntz CP, Desmond JA, Schlebach JP, VanNieuwenhze MS, Straiker A. Structure-activity relationship study of cannabidiol-based analogs as negative allosteric modulators of the μ-opioid receptor. J Med Chem. 2023;66(14):9466–94. DOI: 10.1021/acs.jmedchem.3c00061

[15] Bonaccorso S, Ricciardi A, Zangani C, Chiappini S, Schifano F. Cannabidiol (CBD) use in psychiatric disorders: A systematic review. Neurotoxicology. 2019;74:282–98. DOI: 10.1016/j.neuro.2019.08.002

[16] Martin LJ, Banister SD, Bowen MT. Understanding the complex pharmacology of cannabidiol: Mounting evidence suggests a common binding site with cholesterol. Pharmacol Res. 2021;166:105508. DOI: 10.1016/j.phrs.2021.105508

[17] Khalsa JH, Bunt G, Blum K, Maggirwar SB, Galanter M, Potenza MN. Review: Cannabinoids as medicinals. Curr Addict Rep. 2022;9(4):630–46. DOI: 10.1007/s40429-022-00438-3

[18] Luz-Veiga M, Azevedo-Silva J, Fernandes JC. Beyond pain relief: A review on cannabidiol potential in medical therapies. Pharmaceuticals. 2023;16(2):155. DOI: 10.3390/ph16020155

[19] della Rocca G, Paoletti F, Conti MB, Galarini R, Chiaradia E, Sforna M, et al. Pharmacokinetics of cannabidiol following single oral and oral transmucosal administration in dogs. Front Vet Sci. 2023;9:1104152. DOI: 10.3389/fvets.2022.1104152

[20] Ruiz CM, Torrens A, Lallai V, Castillo E, Manca L, Martinez MX, et al. Pharmacokinetic and pharmacodynamic properties of aerosolized (“vaped”) THC in adolescent male and female rats. Psychopharmacology. 2021;238(12):3595–5. DOI: 10.1007/s00213-021-05976-8

[21] Bardhi K, Coates S, Watson CJW, Lazarus P. Cannabinoids and drug metabolizing enzymes: Potential for drug-drug interactions and implications for drug safety and efficacy. Expert Rev Clin Pharmacol. 2022;15(12):1443–60. DOI: 10.1080/17512433.2022.2148655

[22] Batinic A, Sutlovic D, Kuret S, Burcul F, Kalajzic N, Matana A, et al. Differences in plasma cannabidiol concentrations in women and men: A randomized, placebo-controlled, crossover study. Int J Mol Sci. 2023;24(12):10273. DOI: 10.3390/ijms241210273

[23] Rao Q, Zhang T, Dai M, Li B, Pu Q, Zhao M, et al. Comparative metabolomic profiling of the metabolic differences of Δ9-tetrahydrocannabinol and cannabidiol. Molecules. 2022;27(21):7573. DOI: 10.3390/molecules27217573

[24] Vlad RA, Hancu GH, Ciurba A, Antonoaea P, Rédai EM, Todoran N, et al. Cannabidiol – therapeutic and legal aspects. Pharmazie. 2020;75(10):463–69. DOI: 10.1691/ph.2020.0076

[25] FDA. FDA Regulation of Cannabis and Cannabis-Derived Products, Including Cannabidiol (CBD) [Internet]. 2023 [cited 2023 Jul 15]. Available from: https://www.fda.gov/news-events/public-health-focus/fda-regulation-cannabis-and-cannabis-derived-products-including-cannabidiol-cbd

[26] Chu W. Nutra Ingredients Europe. Updated EC Ruling for CBD as Novel Food [Internet]. 2019 [cited 2023 Jul 15]. Available from: https://www.nutraingredients.com/Article/2019/01/31/Updated-EC-ruling-for-CBD-classes-supplement-ingredient-as-Novel-Food

[27] International Narcotics Control Board. Reports 2021 [Internet]. 2022 [cited 2023 Jul 15]. Available from: https://www.incb.org/documents/Publications/AnnualReports/AR2021/Annual_Report/E_INCB_2021_1_eng.pdf

[28] Poperechna D. Medical cannabis usage has been legalized in Ukraine, but not entirely. Ukrainian Pravda [Internet]. 2021 Apr 9 [cited 2023 Jul 15]. Available from: https://life.pravda.com.ua/health/2021/04/9/244505/

[29] Fortin D, Di Beo V, Massin S, Bisiou Y, Carrieri P, Barré T. Reasons for using cannabidiol: A cross-sectional study of French cannabidiol users. J Cannabis Res. 2021;3(1):46. DOI: 10.1186/s42238-021-00102-z

[30] Gibbs B, Yates DA, Liebling J. CBD in the UK: Towards a responsible, innovative and high-quality cannabidiol industry. Centre for Medicinal Cannabis [Internet]. 2019 Jun [cited 2023 Jul 15]. 72 p. Available from: https://hempindustrydaily.com/wp-content/uploads/2020/04/Report-_-CBD-in-the-UK-002.pdf

[31] Bisiou Y. Drugs, cannabis and cannabidiol (CBD): France under pressure from the CJEU. 2021. Available from: https://www.researchgate.net/publication/349454809_Stupefiants_cannabis_et_cannabidiol_CBD_la_France_sous_pression_de_la_CJUE

[32] Dierking D. MJUS vs. MSOS: Which U.S. Cannabis market ETF looks better? ETF Focus. [Internet]. 2021 Jun 21 [cited 2023 Jul 15]. Available from: https://www.thestreet.com/etffocus/trade-ideas/mjus-msos-which-cannabis-etf-looks-better

[33] Englund A, Oliver D, Chesney E, Chester L, Wilson J, Sovi S, et al. Does cannabidiol make cannabis safer? A randomized, double-blind, cross-over trial of cannabis with four different CBD:THC ratios. Neuropsychopharmacol. 2023;48(4):869–76. DOI: 10.1038/s41386-022-01478-z

[34] Cannabidiol Global Market Report 2023. Report [Internet]. 2023 Feb [cited 2023 Jul 15]. 200 p. Available from: https://www.researchandmarkets.com/reports/5741562/cannabidiol-global-market-report

[35] Kaufmann R, Harris Bozer A, Kube Jotte A, Aqua K. Long-Term, Self-Dosing CBD Users: Indications, dosage, and self-perceptions on general health/symptoms and drug use. Med Cannabis Cannabinoids. 2023;6(1):77–88. DOI:10.1159/000531666

[36] Roser P, Habermeyer B, Scherbaum N, Lay B. Cannabidiol use among patients with substance use disorders. Subst Abuse Treat Prev Policy. 2022;17(1):59. DOI:10.1080/14659891.2022.2120425

[37] Turna J, Syan SK, Frey BN, Rush B, Costello MJ, Weiss M, MacKillop J. Cannabidiol as a novel candidate alcohol use disorder pharmacotherapy: A systematic review. Alcohol Clin Exp Res. 2019;43(4):550–63. DOI: 10.1111/acer.13964

[38] Vitale RM, Iannotti FA, Amodeo P. The (poly)pharmacology of cannabidiol in neurological and neuropsychiatric disorders: Molecular mechanisms and targets. Int J Mol Sci. 2021;22(9):4876. DOI: 10.3390/ijms22094876

[39] Metz VG, da Rosa JLO, Rossato DR, Milanesi LH, Burger ME, Pase CS. Cannabidiol prevents amphetamine relapse and modulates D1- and D2-receptor levels in mesocorticolimbic brain areas of rats. Eur Neuropsychopharmacol. 2021;50. DOI: 10.1016/j.euroneuro

[40] Nouri K, Anooshe M, Karimi-Haghighi S, Mousavi Z, Haghparast A. Involvement of hippocampal D1-like dopamine receptors in the inhibitory effect of cannabidiol on acquisition and expression of methamphetamine-induced conditioned place preference. Neurochem Res. 2021;46(8):2008-2018. DOI: 10.1007/s11064-021-03350-w

[41] Rizkallah E, Mongeau-Pérusse V, Lamanuzzi L, Castenada-Ouellet SA, Stip E, Juteau LC, et al. Cannabidiol effects on cognition in individuals with cocaine use disorder: Exploratory results from a randomized controlled trial. Pharmacol Biochem Behav. 2022;216:173376. DOI: 10.1016/j.pbb.2022.173376

[42] Qian Y, Gilliland TK, Markowitz JS. The influence of carboxylesterase 1 polymorphism and cannabidiol on the hepatic metabolism of heroin. Chem Biol Interact. 2020;316:108914. DOI: 10.1016/j.cbi.2019.108914

[43] Brice-Tutt AC, Montgomery DS, Kramer CM, Novotny PM, Malphurs WL, Sharma A. An ethogram analysis of cutaneous thermal pain sensitivity and oxycodone reward-related behaviors in rats. Version 1. Res Sq [Preprint]. 2023. DOI: 10.21203/rs.3.rs-2679319/v1

[44] Pallanti S, Marras A, Makris N. A research domain criteria approach to gambling disorder and behavioral addictions: Decision-making, response inhibition, and the role of cannabidiol. Front Psychiatry. 2021;12:634418. DOI: 10.3389/fpsyt.2021.634418

[45] Madden K, Tanco K, Bruera E. Clinically significant drug-drug interaction between methadone and cannabidiol. Pediatrics. 2020;145(6):e20193256. DOI: 10.1542/peds.2019-3256

[46] Darweesh RS, Khamis TN, El-Elimat T. The effect of cannabidiol on the pharmacokinetics of carbamazepine in rats. Naunyn Schmiedebergs Arch Pharmacol. 2020;393(10):1871–86. DOI: 10.1007/s00210-020-01878-2

[47] Stohs SJ, Ray D. Is cannabidiol hepatotoxic or hepatoprotective: A review. Toxicol Res Appl. 2020;4. DOI: 10.1177/2397847320922944

[48] Flores VA, Kisiolek JN, Ramani A, Townsend R, Rodriguez E, Butler B, Stewart LK. Effects of oral cannabidiol on health and fitness in healthy adults: An 8-week randomized trial. Nutrients. 2023;15(12):2664. DOI: 10.3390/nu15122664

[49] Matheson J, Bourgault Z, Le Foll B. Sex differences in the neuropsychiatric effects and pharmacokinetics of cannabidiol: A scoping review. Biomolecules. 2022;12(10):1462. DOI: 10.3390/biom12101462

[50] Pandelides Z, Thornton C, Faruque AS, Whitehead AP, Willett KL, Ashpole NM. Developmental exposure to cannabidiol (CBD) alters longevity and health span of zebrafish (Danio rerio). GeroScience. 2020;42(2):785–800. DOI: 10.1007/s11357-020-00182-4

[51] Carvalho RK, Rocha TL, Fernandes FH, Gonçalves BB, Souza MR, Araújo AA, et al. Decreasing sperm quality in mice subjected to chronic cannabidiol exposure: New insights of cannabidiol-mediated male reproductive toxicity. Chem Biol Interact. 2022;351:109743. DOI: 10.1016/j.cbi.2021.109743

[52] Pandelides Z, Aluru N, Thornton C, Watts HE, Willett KL. transcriptomic changes and the roles of cannabinoid receptors and PPARγ in developmental toxicities following exposure to Δ9-tetrahydrocannabinol and cannabidiol. Toxicol Sci. 2021;182(1):44–59. DOI: 10.1093/toxsci/kfab046

[53] Merrick J, Lane B, Sebree T, Yaksh T, O'Neill C, Banks SL. Identification of psychoactive degradants of cannabidiol in simulated gastric and physiological fluid. Cannabis Cannabinoid Res. 2016;1(1):102–12. DOI: 10.1089/can.2015.0004

[54] Henderson RG, Franke KS, Payne LE, Franzen A. Cannabidiol safety data: A systematic mapping study. Cannabis Cannabinoid Res. 2023;8(1):34–40. DOI: 10.1089/can.2022.0100

[55] Reece AS, Hulse GK. Geotemporospatial and causal inferential epidemiological overview and survey of USA cannabis, cannabidiol and cannabinoid genotoxicity expressed in cancer incidence 2003-2017: Part 3 – spatiotemporal, multivariable and causal inferential pathfinding and exploratory analyses of prostate and ovarian cancers. Arch Public Health. 2022;80(1):101. DOI: 10.1186/s13690-022-00813-6

[56] Madera-Acosta A, Johnson-Wall H, Carbone LD, Meszaros A, Berman AE, White J. Cannabidiol (CBD) oil toxicity mimicking extraglandular complications of Sjögren's syndrome. Rheumatol Adv Pract. 2021;5(1):rkab010. DOI: 10.1093/rap/rkab010

[57] Dellepiane S, Paranjpe I, Rajagopal M, Kamat S, O'Hagan R, Gulamali F, et al. Cannabis use and ckd: Epidemiological associations and mendelian randomization. Kidney med. 2022;5(2):100582. DOI: 10.1016/j.xkme.2022.100582

[58] Carmona-Hidalgo B, García-Martín A, Muñoz E, González-Mariscal I. Detrimental effect of cannabidiol on the early onset of diabetic nephropathy in male mice. Pharmaceuticals (Basel). 2021;14(9):863. DOI: 10.3390/ph14090863

[59] Mascal M, Hafezi N, Wang D, Hu Y, Serra G, Dallas ML, Spencer JP. Synthetic, non-intoxicating 8,9-dihydrocannabidiol for the mitigation of seizures. Sci Rep. 2019;9(1):7778. DOI: 10.1038/s41598-019-44056-y

[60] Crippa JA, Guimarães FS, Campos AC, Zuardi AW. Translational investigation of the therapeutic potential of cannabidiol (cbd): Toward a new age. Front Immunol. 2018;9:2009. DOI: 10.3389/fimmu.2018.02009

[61] Schoedel KA, Szeto I, Setnik B, Sellers EM, Levy-Cooperman N, Mills C, et al. Abuse potential assessment of cannabidiol (CBD) in recreational polydrug users: A randomized, double-blind, controlled trial. Epilepsy Behav. 2018;88:162–71. DOI: 10.1016/j.yebeh.2018.07.027

[62] Hunter D, Oldfield G, Tich N, Messenheimer J, Sebree T. Synthetic transdermal cannabidiol for the treatment of knee pain due to osteoarthritis. J Osteoarthr Cartil. 2018;26(Suppl 1). DOI: 10.1016/j.joca.2018.02.067

[63] Turck D, Bohn T, Castenmiller J, De Henauw S, Hirsch-Ernst KI, Knutsen HK, et al. Statement on safety of cannabidiol as a novel food: Data gaps and uncertainties. EFSA Journal. 2022;20(6):e07322. DOI: 10.2903/j.efsa.2022.7322

[64] Dziwenka M, Coppock R, Davidson MH, Weder MA. Toxicological safety assessment of HempChoice® hemp oil extract; a proprietary extract consisting of a high concentration of cannabidiol (CBD) in addition to other phytocannabinoids and terpenes derived from Cannabissativa L. Heliyon. 2023;9(6):e16913. DOI: 10.1016/j.heliyon.2023.e16913

[65] Sharifi A, Karimi-Haghighi S, Shabani R, Asgari HR, Ahadi R, Haghparast A. Cannabidiol impairs the rewarding effects of methamphetamine: Involvement of dopaminergic receptors in the nucleus accumbens. Prog Neuropsychopharmacol Biol Psychiatry. 2022;113:110458. DOI: 10.1016/j.pnpbp.2021.110458

[66] Mboumba Bouassa RS, Needham J, Nohynek D, Singer J, Lee T, Bobeuf F, et al. Safety and tolerability of oral cannabinoids in people living with hiv on long-term art: A randomized, open-label, interventional pilot clinical trial (CTNPT 028). Biomedicines. 2022;10(12):3168. DOI: 10.3390/biomedicines10123168

[67] Rein JL. The nephrologist's guide to cannabis and cannabinoids. Curr Opin Nephrol Hypertens. 2020;29(2):248–57. DOI: 10.1097/MNH.0000000000000590

[68] Sund LJ, Dargan PI, Archer JRH, Wood DM. E-cigarette or vaping-associated lung injury (EVALI): A review of international case reports from outside the United States of America. Clin Toxicol (Phila). 2023;61(2):91–97. DOI: 10.1080/15563650.2022.2160342